other_material
confidence high
sentiment positive
materiality 0.80
ArriVent reports 16.0-month mPFS with firmonertinib in EGFR PACC NSCLC Phase 1b final analysis
ArriVent BioPharma, Inc.
- Median PFS 16.0 months by BICR with firmonertinib 240 mg once daily in first-line EGFR PACC NSCLC.
- Confirmed ORR 68.2% at 240 mg; median DOR 14.6 months by BICR; responses across multiple PACC mutation types.
- CNS confirmed ORR 42.9% (6/14) with 35.7% CNS complete responses by BICR in evaluable patients.
- First patient enrollment in global pivotal Phase 3 ALPACCA trial expected in H2 2025.
- Safety profile maintained; most common TEAEs: diarrhea, hepatic enzyme elevation, rash; no new signals.
item 7.01item 8.01item 9.01